Clene Inc. CLNN Archives - Page 9 of 10

ThursdayNov 16, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program

Clene recently released its financial results for the third quarter ended September 30, 2023, and provided recent operating highlights for its ALS clinical program The ALS clinical program includes two independent studies evaluating the safety and efficacy of the company’s lead investigational product CNM-Au8(R) The 24-month long-term data cut from the open-label extension of the RESCUE-ALS study showed a significant median survival benefit of 19.3 months, a significant 52% decreased risk of ALS clinical worsening events, and a 75% decreased risk of long-term all-cause mortality Clene also summarized long-term follow-up data from the HEALEY ALS platform trial, which demonstrated significantly…

FridayNov 10, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS

Clene, a company targeting the treatment of neurodegenerative diseases that severely impact people’s lives, is currently focusing on amyotrophic lateral sclerosis (“ALS”) alongside other neurodegenerative diseases The company’s wholly owned subsidiary, Clene Nanomedicine, and two collaborators, Columbia University and Synapticure, are the recipients of a four-year grant totaling $45.1 million The grant will support an Expanded Access Protocol (“EAP”) study for Clene’s investigational product, CNM-Au8(R) CNM-Au8 is an orally administered gold nanocrystal suspension that is thought to improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, including ALS The EAP study will give patients who did not initially…

TuesdayNov 07, 2023 10:29 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today released its third quarter 2023 financial results and provided recent operating highlights for its ALS clinical program. Among the highlights, the company reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8(R) in the RESCUE ALS open-label extension trial. “We are pleased to be approaching a meaningful regulatory discussion with the U.S. Food and Drug Administration (‘FDA’) later in the fourth quarter to elucidate key next steps in our ALS regulatory submission of CNM-Au8,”…

MondayOct 30, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment commencing in the summer of 2020 Over the years since, Clene has consistently released additional data from the Trial, most recently reporting significant long-term survival improvement among patients treated with CNM-Au8 compared to PRO-ACT historical controls The company also announced the publication of a peer-reviewed study in the nanotechnology-focused journal Small; the study describes CNM-Au8’s mechanism of action Clene received a $45.1…

WednesdayOct 25, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS

Clene's wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”) The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8 Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on…

TuesdayOct 17, 2023 11:14 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. The announcement noted that Clene’s nanotechnological approach was recently awarded a substantial grant by the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) to conduct an Expanded Access Protocol in ALS. The announcement also noted that Clene is…

MondayOct 16, 2023 11:15 am

Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS

In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R) Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024 October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov,…

TuesdayOct 10, 2023 2:10 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview of recent developments, which provide hope to those affected by neurodegenerative conditions. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “Clene spends every waking moment working on amyotrophic lateral sclerosis (‘ALS’), a devastating neurodegenerative condition,” said Clene president…

ThursdayOct 05, 2023 11:29 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) for the company’s investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis (“ALS”). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S.…

ThursdaySep 28, 2023 11:49 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the…

Site Search

Company Search

Tag: Clene Inc. CLNN